Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Agile Therapeutics (Nasdaq: AGRX) announced that its Chairman and CEO, Al Altomari, will participate in a fireside chat at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agile Therapeutics (Nasdaq: AGRX) announced that its Chairman and CEO, Al Altomari, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The event will be available for on-demand listening starting January 11, 2021, at 6:00 AM Eastern Time on the Investors section of Agile's website. An archived version will remain accessible for 30 days. Agile Therapeutics focuses on women's healthcare, with its initial product, Twirla, a non-daily prescription contraceptive patch, utilizing proprietary Skinfusion technology.
Details
News Market Reaction – AGRX
The recorded move for AGRX in the trading session of this news was -2.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participate in a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.
The fireside chat will be available for on-demand listening beginning Monday, January 11, 2021, at 6:00 AM Eastern Time on the Investors section of the Agile Therapeutics website at www.agiletherapeutics.com, under the Events & Presentations tab. The archived webcast will be available for 30 days.
About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.
Follow Agile on LinkedIn and Twitter: @AgileTher.
Contact:
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.